US Stock MarketDetailed Quotes

BBIO BridgeBio Pharma

Watchlist
  • 31.400
  • -0.170-0.54%
Close Mar 10 16:00 ET
  • 31.380
  • -0.020-0.06%
Post 20:01 ET
5.97BMarket Cap-10.90P/E (TTM)

About BridgeBio Pharma Company

BridgeBio Pharma, Inc. engages in identifying and advancing transformative medicines to treat patients who suffer from Mendelian diseases. Its pipeline of development programs includes product candidates ranging from early discovery to late-stage development. The company was founded by Charles Homcy, Francis Patrick McCormick, Philip Reilly, and Neil Kumar in 2015 and is headquartered in Palo Alto, CA.

Company Profile

SymbolBBIO
Company NameBridgeBio Pharma
Listing DateJun 27, 2019
Issue Price17.00
Founded2015
CEODr. Neil Kumar, PhD
MarketNASDAQ
Employees730
Fiscal Year Ends12-31
Address3160 Porter Drive,Suite 250
CityPalo Alto
ProvinceCalifornia
CountryUnited States of America
Zip Code94304
Phone1-650-391-9740
Websitehttp://www.bridgebio.com

Company Executives

  • Name
  • Position
  • Salary
  • Dr. Neil Kumar, PhD
  • Director and Chief Executive Officer of the Company and Eidos Therapeutics, Inc.
  • 12.16M
  • Dr. Thomas Trimarchi, PhD
  • Principal Financial Officer, President and Chief Operating Officer
  • --
  • Maricel M. Apuli
  • Chief Accounting Officer
  • --
  • Dr. Richard H. Scheller, PhD
  • Chairman of Research & Development
  • 2.01M
  • Dr. Charles J. Homcy,M.D.
  • Lead Independent Director and Chairman of Pharmaceuticals
  • 1.11M
  • Dr. Frank P. McCormick, D.Sc.
  • Director
  • 1.74M
  • Andrea John Ellis
  • Independent Director
  • 600.00K
  • Ronald J. Daniels
  • Independent Director
  • 600.00K
  • Ali J. Satvat
  • Independent Director
  • 600.00K
  • Dr. Hannah A. Valantine, M.D.
  • Independent Director
  • 600.00K
  • James C. Momtazee
  • Independent Director
  • 600.00K
  • Fred Hassan
  • Independent Director
  • 600.00K
  • Douglas A. Dachille
  • Independent Director
  • 600.00K
  • Dr. Randal W. Scott,PhD
  • Independent Director
  • 600.00K
  • Dr. Eric Aguiar, M.D.
  • Independent Director
  • 600.00K
  • Jennifer E. Cook
  • Independent Director
  • 600.00K
  • Dr. Andrew W. Lo, PhD
  • Independent Director
  • 600.00K
Trending Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries

Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.

Symbol Mini Chart % Chg
D.R. Horton
DHI
+0.40%
Lennar Corp
LEN
+0.02%
KB Home
KBH
-0.06%
Petroleo Brasileiro SA Petrobras
PBR
-1.46%
Ecopetrol
EC
-1.81%

Unlock the Full List